The Patent Finder
IB

Ipsen Biopharm Ltd.

First filing 2005
OverviewNotableFeesChangesFamiliesPatent listSources & methods

35 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Jan 2027
Next term end
20
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 8, 2027
    The maintenance fee for Pharmaceutical Composition Comprising Botulinum, a Non Ionic Surfactant, Sodium Chloride and Sucrose (US 9,125,804) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
  • 1 fee due Apr 29, 2027
    The maintenance fee for Stabilizing Camptothecin Pharmaceutical Compositions (US 10,456,360) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
  • 1 fee due May 19, 2027
    The maintenance fee for Combination Therapy for Cancer Treatment (US 10,478,428) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
  • 1 fee due Jun 19, 2027
    The maintenance fee for Combination Therapy for Cancer Treatment (US 11,844,795) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
  • 1 fee due Nov 7, 2027
    The maintenance fee for Suppression of Bone Cancer-induced Allodynia (US 11,975,055) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 20 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 8,329,213Liposomes Useful for Drug Delivery
In force
 · High confidence
In forceHigh confidence
US 9,125,804Pharmaceutical Composition Comprising Botulinum, a Non Ionic Surfactant, Sodium Chloride and Sucrose
In force
 · High confidence
In forceHigh confidence
US 8,147,867Liposomes Useful for Drug Delivery
In force
 · High confidence
In forceHigh confidence
US 8,658,203Liposomes Useful for Drug Delivery to the Brain
In force
 · High confidence
In forceHigh confidence
US 9,339,497Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · High confidence
In forceHigh confidence
US 9,364,473Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · Medium confidence
In forceMedium confidence
US 9,452,162Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · Medium confidence
In forceMedium confidence
US 9,492,442Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · Medium confidence
In forceMedium confidence
US 9,717,724Methods for Treating Pancreatic Cancer Using Combination Therapies
In force
 · Low confidence
In forceLow confidence
US 10,980,795Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · Medium confidence
In forceMedium confidence
10 of 35 patents shown.
Pro members see all 35.
Pro members: see all 35 patents
Also on record, not counted in the 35: 25 patents ended · 40 applications pending · 67 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited